Bioinformatics specialist BioLizard opens a new office at the Biopôle in Lausanne
Life sciences
24 January 2024
BioLizard’s move to Lausanne reflects its growing international presence and dedication to serving the Swiss biotech industry. | © Biopôle
BioLizard, a leader in bioinformatics, data analytics, and data management services, has opened a new office on the Biopôle life sciences campus in Lausanne.
Switzerland, renowned for its flourishing biotech sector, hosts the headquarters of 20% of European biotech companies. In 2022, the nation recorded R&D investments of CHF 2.7 billion, emphasizing its role as a location of choice for biotech innovation.
BioLizard is a leading multi-national company in bioinformatics, data analytics, and data management, guiding digital transformation in the life sciences industry. With a team of over 50 experts, BioLizard collaborates with a diverse range of companies, from drug discovery to clinical research and diagnostics. Originally based in Ghent, Belgique, the company’s entrance into the Swiss market signifies a vital step, positioning itself among both established pharmaceutical corporations and dynamic biotech start-ups.
Liesbeth Ceelen, PhD, CEO of BioLizard, expressed the company’s ambition in Switzerland: “With our new subsidiary, we aim to increase our reach and service power within Switzerland. Our team, the ‘Lizards,’ are experts in bioinformatics, AI, data analytics, and software development. We focus on creating tailor-made solutions for our clients, supporting industries like therapeutics, diagnostics, animal health, and food & agriculture.”
Yves Muyssen, COO of BioLizard, highlighted Switzerland’s critical role in global healthcare innovation, explaining: “Switzerland plays a leading role in driving global healthcare innovation. We know IT- and AI-based data solutions are crucial to advancing research by accelerating speed, decreasing risk, and improving quality of results.”
BioLizard supports its Swiss clients in strategic consulting, disease profiling, and drug discovery & development, from early stages to clinical trials. The company recently launched BioVerse, a software platform with applications for scientific literature searches, microbiome analysis, and multi-omics data analysis.
GGBa and Innovaud supported BioLizard in its establishment process, enabling the new office to get up and running in Switzerland as quickly as possible.
